title: Favourable prognostic factors in therapy related acute myeloid leukaemia.
abstract: BACKGROUND
  Therapy related acute myeloid leukaemia (t-AML) is a distinct clinical entity recognized by the World Health Organization classification occurring after chemotherapy and/or radiation treatment administered for a previous disease. T-AML is characterised by pancytopenia, three-lineage myelodysplasia, high frequency of unfavourable cytogenetics and short survival.
  
  
  OBJECTIVE
  The aim of this study was to analyse clinical, cytogenetic, and cytological characteristics of t-AML and their impact on survival.
  
  
  METHODS
  Seventeen patients with t-AML (8 male and 9 female; median age 59 years) were identified among 730 consecutive patients with acute myeloid leukaemia. The degree of three-lineage dysplasia as well as haematological, cytological and cytogenetic analyses, were assessed by standard methods.
  
  
  RESULTS
  The patients survived a median of 62.5 days with the 10% probability of survival during two years. Prognostically favourable factors were a higher percentage of dysplastic granulocytic cells, age less than 60 years, and presence of prognostically favourable karyotype inv(16), t(15;17), t(8;21).
  
  
  CONCLUSIONS
  The stated prognostic factors that include age, cytogenetics findings and granulocytic dysplasia analysis could contribute to adequate risk stratification of t-AML, though fuller results would require additional analyses.
authors.affiliation: Clinic of Haematology, Clinical Centre of Serbia, Belgrade, Serbia. drantoni@gmail.com
authors.forename: Nebojsa
authors.initials: N
authors.lastname: Antonijević
authors.forename: Nada
authors.initials: N
authors.lastname: Suvajdziĉ
authors.forename: Tatjana
authors.initials: T
authors.lastname: Terzić
authors.forename: Branko
authors.initials: B
authors.lastname: Jakovljević
authors.forename: Gradimir
authors.initials: G
authors.lastname: Janković
authors.forename: Ivo
authors.initials: I
authors.lastname: Elezović
authors.forename: Rajko
authors.initials: R
authors.lastname: Milosević
authors.forename: Milica
authors.initials: M
authors.lastname: Colović
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001853:Bone Marrow / Q000473:pathology; D020732:Cytogenetic Analysis; D005260:Female; D006098:Granulocytes / Q000473:pathology; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D011878:Radiotherapy / Q000009:adverse effects; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents